RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
RAPT Therapeutics (Nasdaq: RAPT) will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference. Brian Wong, M.D., Ph.D., President and CEO, is scheduled to present on Wednesday, January 14, 2026 at 2:15 p.m. PT. Investors can access a live webcast and an archived recording via the company’s investor website.
This presentation is a corporate overview at a major industry conference and does not include new financial guidance or clinical readouts in the announcement.
Positive
- None.
Negative
- None.
News Market Reaction 7 Alerts
On the day this news was published, RAPT gained 5.16%, reflecting a notable positive market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $45M to the company's valuation, bringing the market cap to $920M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RAPT gained 3.39% while peers were mixed: OMER -10.34%, THRD -0.55%, ANNX -1.35%, CADL +5.88%, NMRA +8.33%. With no peers in the momentum scanner and no same-day peer news, the move appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings and update | Positive | +2.7% | Q3 2025 results plus IND clearance and cash runway extension to mid-2028. |
| Nov 04 | Investor conferences | Neutral | -2.9% | Announcement of participation in three November 2025 investor conferences. |
| Oct 27 | Clinical trial start | Positive | +1.9% | Initiation of prestIgE Phase 2b ozureprubart trial in food allergy. |
| Oct 21 | Public offering priced | Negative | -0.4% | Pricing of public offering of 8,333,334 shares at $30.00 per share. |
| Oct 21 | Offering announced | Negative | -0.4% | Announcement of proposed underwritten public offering of common stock. |
Recent news-driven moves have been modest, with positive clinical and financing updates generally followed by small positive price reactions, and offerings seeing slight declines.
Over the last several months, RAPT has combined financing, clinical progress, and investor outreach. On Oct 21, 2025, it announced and priced a public offering of 8,333,334 shares at $30.00, with a modest negative price impact. By Oct 27, 2025, the company initiated the prestIgE Phase 2b trial of ozureprubart in food allergy, which was followed by a small gain. Q3 2025 results and updates on Nov 6, 2025 coincided with another mild increase. Today’s J.P. Morgan conference appearance continues the pattern of active investor engagement.
Market Pulse Summary
The stock moved +5.2% in the session following this news. A strong positive reaction aligns with RAPT’s established uptrend, with shares already above the 200-day MA of $17.34 and well off the 52-week low of $5.6652. Prior news events, such as the prestIgE Phase 2b initiation and Q3 2025 update, saw only modest moves, so a large gain after this conference appearance would stand out versus recent history. Investors would then need to watch for how previously completed equity offerings influence longer-term supply and demand dynamics.
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 44thAnnual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pacific Time.
To access the live webcast or subsequent archived recording of the presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.
About RAPT Therapeutics, Inc.
RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.
RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com
RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com
FAQ
When will RAPT (NASDAQ: RAPT) present at the J.P. Morgan Healthcare Conference in 2026?
Who will present for RAPT Therapeutics (RAPT) at the JP Morgan 2026 conference?
How can investors watch the RAPT (RAPT) presentation at the 44th J.P. Morgan Healthcare Conference?
Will RAPT (NASDAQ: RAPT) release new financial guidance or clinical data during the January 14, 2026 presentation?
Where can I find the archived recording of RAPT Therapeutics (RAPT) presentation after January 14, 2026?
